Eloralintide

Metabolic & weight Investigational (in clinical trials)

Selective amylin receptor agonist · also known as LY3841136

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Eloralintide is a selective amylin-receptor agonist that is not yet approved anywhere. In a 48-week phase 2 trial in 263 US adults with obesity or overweight, four fixed weekly dose levels between 1 and 9 mg (plus two escalation arms) produced dose-dependent weight loss, and phase 3 studies have since been registered.

Commonly reported dosing (10 mg vial)

Reconstituted with 1 mL → 10 mg/mL.

Phase	Dose	Volume	U-100 units
Lowest fixed-dose arm	1 mg	0.1 mL	10
Mid fixed-dose arm	3 mg	0.3 mL	30
Higher fixed-dose arm	6 mg	0.6 mL	60
Highest fixed-dose arm	9 mg	0.9 mL	90

Frequency: Once weekly, subcutaneous · Half-life: Long-acting; studied as a once-weekly injection

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
1 mL of bacteriostatic water is added slowly down the inside wall of the 10 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 10 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Vial figures commonly describe refrigeration (2-8 °C) with protection from light.

After mixing: No compound-specific stability period after reconstitution has been established; refrigeration and light protection are commonly reported.

How it works

By activating amylin receptors it is thought to act on appetite-regulating brain circuits and gastric emptying, similar in concept to other amylin analogues but with more selective receptor activity.

Researched for

A 48-week phase 2 randomized, placebo-controlled trial in adults with obesity or overweight without diabetes.
Phase 3 programme in obesity, with and without type 2 diabetes, in sleep apnea, and as an add-on to incretin therapy.

Notes

The four amounts above are separate fixed-dose arms from the phase 2 trial; the trial also tested escalation from 3 mg and 6 mg up to 9 mg.
The 1 mL reconstitution is a worked calculation for research vials (10 mg/mL); the trial publication did not describe vial preparation.
Nausea and fatigue were the most commonly reported adverse events, mostly mild to moderate, and tolerability was better with dose escalation.